- Home
- NECB vs CRDF Comparison
NECB vs CRDF Comparison
Compare NECB & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NECB | CRDF |
|---|---|---|
| Founded | 1934 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.4M | 142.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NECB | CRDF |
|---|---|---|
| Price | $23.02 | $3.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 46.3K | ★ 1.0M |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.21 | N/A |
| Revenue | ★ $102,569,000.00 | $501,000.00 |
| Revenue This Year | $1.90 | N/A |
| Revenue Next Year | $6.93 | N/A |
| P/E Ratio | $7.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.27 | $1.90 |
| 52 Week High | $25.93 | $4.99 |
Technical Indicators
Market Signals| Indicator | NECB | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 81.65 |
| Support Level | $22.81 | $2.32 |
| Resistance Level | $24.13 | $2.95 |
| Average True Range (ATR) | 0.64 | 0.18 |
| MACD | -0.09 | 0.09 |
| Stochastic Oscillator | 62.56 | 92.50 |
Price Performance
Historical ComparisonAbout NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.